<?xml version="1.0" encoding="UTF-8"?>
<p id="para80">Despite remarkable progress in scaling up HIV testing and treatment worldwide, 1Â·7 million new HIV infections occurred in 2018, signalling what UNAIDS has termed a prevention crisis.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> Oral pre-exposure prophylaxis (PrEP) is highly effective
 <xref rid="bib2" ref-type="bibr">
  <sup>2</sup>
 </xref> and has the potential to accelerate reductions in HIV incidence as part of combination approaches to HIV prevention. Reduced HIV incidence has been observed in high-income populations of men who have sex with men for whom antiretroviral therapy (ART) and PrEP have been scaled-up.
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib4" ref-type="bibr">4</xref> PrEP is recommended in global guidelines
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref> and is being introduced across southern and eastern Africa, where the burden of new infections is the greatest.
</p>
